相关实验视频

Updated: Jan 9, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

对VS-186B的功能性表征,这是一种具有抗癌活性的新型HDAC抑制剂

Laura A Sanchez-Michael¹, Vijayalakshmi Sudarshan^2,3,4, Allison Elias¹

¹Department of Biological Sciences, Border Biomedical Research Center, The University of Texas at El Paso, El Paso, TX 79968, USA.

International journal of molecular sciences

|December 11, 2025

概括

一种新的化合物,VS-186B,通过抑制组织激素脱乙酶 (HDACs),诱导亡,有效地向癌细胞. 这种新型表观遗传疗法对白血病和淋巴瘤的治疗有望,对健康细胞的毒性最小.

科学领域:

表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

激素乙化/脱乙化调节基因表达,对癌症的发展和治疗耐药性至关重要.
激素脱乙酶 (HDACs) 的过度表达使瘤抑制剂沉默,促进癌细胞的增殖.
表观遗传变化使瘤能够逃避治疗并发展抗药性.

研究的目的:

识别新型化合物选择性向癌细胞,降低毒性.
为了评估一系列新型的组织素脱乙酶抑制剂 (HDACis) 的抗癌潜力.

主要方法:

使用了差异核染色 (DNS) 试验,流动细胞计和HDAC抑制试验.
评估了细胞毒性,选择性和细胞死亡机制.
连接地图 (CMap) 分析和酶分析证实了HDAC抑制.

主要成果:

VS-186B显示出对Jurkat T细胞白血病的优越细胞毒性和选择性 (选择性细胞毒性指数).
通过Annexin V-FITC,ROS,JC-1和Caspase-3/7通路诱导VS-186B的亡.
根据剂量,VS-186B抑制了I类和II类HDACs,并显示了与已知的HDACis的基因表达相似性.

结论:

VS-186B是一种强效和选择性的HDAC抑制剂,诱导癌细胞的亡.
VS-186B对非癌细胞系的毒性最小,这表明它具有治疗潜力.
VS-186B需要进一步研究作为白血病和淋巴瘤的表观遗传治疗方法.

关键词:

这是一种HDAC抑制剂.朱尔卡特·朱尔卡特 (Jurkat Jurkat) 是一个名为朱尔卡特的地区.这就是Vorinostat.这是一种抗癌药物.灭症 (apoptosis) 是一种死亡的过程.库尔库明是一种黄素.细胞毒性细胞毒性这种白血病是白血病.选择性的选择性

更多相关视频

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique

Published on: January 14, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Histone Variants at the Centromere

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...